AN INDIVIDUAL affected person information meta-analysis has revealed that increased BMI considerably reduces the effectiveness of JAK inhibitors in rheumatoid arthritis, with weight problems appearing as a real modifier of therapy response reasonably than merely a marker of worse prognosis.
Weight problems has been recognised as frequent amongst sufferers with rheumatoid arthritis and has been related to poorer illness outcomes. Earlier pooled analyses have instructed that JAK inhibitor efficacy is broadly maintained throughout commonplace physique mass index classes, though these research haven’t formally examined whether or not physique mass index modifies therapy impact versus placebo.
Meta-Evaluation of JAK Inhibitor Trials
Researchers carried out a person affected person information meta-analysis of section 3 randomised trials of tofacitinib, baricitinib, upadacitinib, and filgotinib in adults with rheumatoid arthritis, recognized by way of ClinicalTrials.gov and obtained by the Vivli data-sharing platform.
Physique mass index was analysed as a steady and categorical variable utilizing one-stage mixed-effects fashions, validated utilizing a two-stage meta-analysis. Main outcomes have been a 20% enchancment based mostly on American Faculty of Rheumatology core set variables and Illness Exercise Rating based mostly on 28 joints and C-reactive protein.
Greater BMI Linked to Lowered JAK Inhibitor Efficacy
Sixteen trials contributed particular person affected person information from 11,883 individuals (80.7% ladies; imply age 52.9 years), of whom 7,765 obtained tofacitinib, upadacitinib, or baricitinib; filgotinib trials have been excluded as a result of inadequate variables. Median physique mass index was 26.8 kg/m² (IQR 23.2 to 31.3), and 30.9% had class 1-3 weight problems.
Greater physique mass index was related to decreased JAK inhibitor efficacy throughout all endpoints. In contrast with wholesome weight, the adjusted relative threat for a 20% enchancment response was 0.94 (95% CI 0.91 to 0.98) for chubby, 0.92 (0.89 to 0.96) for sophistication 1 weight problems, 0.88 (0.81 to 0.96) for sophistication 2 weight problems, and 0.78 (0.71 to 0.85) for sophistication 3 weight problems.
For illness exercise scores, adjusted imply variations versus wholesome weight have been 0.14 (95% CI 0.06 to 0.22) for chubby, rising to 0.54 (0.37 to 0.70) for sophistication 3 weight problems. No corresponding gradient was seen within the placebo group, and between-study heterogeneity was low to average.
Implications for Rheumatoid Arthritis Care
These findings have proven that increased physique mass index is related to poorer response and decreased therapy profit from JAK inhibitors, with weight problems recognized as a real impact modifier reasonably than merely a marker of prognosis.
The authors have instructed that weight administration ought to be built-in into routine rheumatoid arthritis care alongside pharmacological therapy.
Reference
Bechman Ok et al. Impression of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: a person affected person information meta-analysis of randomised managed trials. The Lancet Rheumatology. 2026;DOI:10.1016/S2665-9913(26)00151-7.
Featured picture: Olivier Le Moal on Adobe Inventory
